{"id":"ta-7284-low","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Polydipsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has additional cardiovascular and renal protective effects. TA-7284 is being developed as a treatment for type 2 diabetes mellitus.","oneSentence":"TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:16.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01512849","phase":"PHASE1","title":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01387737","phase":"PHASE3","title":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1299},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TA-7284 Low","genericName":"TA-7284 Low","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}